株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

アテローム性動脈硬化症:パイプライン製品の分析

Atherosclerosis - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 232865
出版日 ページ情報 英文 225 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.99円で換算しております。
Back to Top
アテローム性動脈硬化症:パイプライン製品の分析 Atherosclerosis - Pipeline Review, H1 2017
出版日: 2017年05月23日 ページ情報: 英文 225 Pages
概要

アテローム性動脈硬化症は、プラークが蓄積することで動脈が肥厚し硬化する疾患です。血流を阻害し、深刻な心血管障害を引き起こします。症状は胸痛、四肢または動脈が閉塞した箇所の痛み、息切れ、疲労感、意識障害、血流不足による足の筋力低下などです。

当レポートでは、アテローム性動脈硬化症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

アテローム性動脈硬化症の概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9297IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H1 2017, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.

Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 5, 43 and 11 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 21 and 5 molecules, respectively.

Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Atherosclerosis - Overview
  • Atherosclerosis - Therapeutics Development
  • Atherosclerosis - Therapeutics Assessment
  • Atherosclerosis - Companies Involved in Therapeutics Development
  • Atherosclerosis - Drug Profiles
  • Atherosclerosis - Dormant Projects
  • Atherosclerosis - Discontinued Products
  • Atherosclerosis - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Atherosclerosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Atherosclerosis - Pipeline by AFFiRiS AG, H1 2017
  • Atherosclerosis - Pipeline by Allergan Plc, H1 2017
  • Atherosclerosis - Pipeline by Amgen Inc, H1 2017
  • Atherosclerosis - Pipeline by Annexin Pharmaceuticals AB, H1 2017
  • Atherosclerosis - Pipeline by Arisaph Pharmaceuticals Inc, H1 2017
  • Atherosclerosis - Pipeline by Athera Biotechnologies AB, H1 2017
  • Atherosclerosis - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Atherosclerosis - Pipeline by Cardax Inc, H1 2017
  • Atherosclerosis - Pipeline by Cerenis Therapeutics Holding SA, H1 2017
  • Atherosclerosis - Pipeline by ChemoCentryx Inc, H1 2017
  • Atherosclerosis - Pipeline by CohBar Inc, H1 2017
  • Atherosclerosis - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Atherosclerosis - Pipeline by DoNatur GmbH, H1 2017
  • Atherosclerosis - Pipeline by Dybly AG, H1 2017
  • Atherosclerosis - Pipeline by Esperion Therapeutics Inc, H1 2017
  • Atherosclerosis - Pipeline by Forty Seven Inc, H1 2017
  • Atherosclerosis - Pipeline by GenKyoTex SA, H1 2017
  • Atherosclerosis - Pipeline by Immusoft Corp, H1 2017
  • Atherosclerosis - Pipeline by Iproteos SL, H1 2017
  • Atherosclerosis - Pipeline by Jenrin Discovery Inc, H1 2017
  • Atherosclerosis - Pipeline by Kang Stem Biotech Co Ltd, H1 2017
  • Atherosclerosis - Pipeline by KineMed Inc, H1 2017
  • Atherosclerosis - Pipeline by Kowa Company Ltd, H1 2017
  • Atherosclerosis - Pipeline by Lead Discovery Center GmbH, H1 2017
  • Atherosclerosis - Pipeline by LipimetiX Development Inc, H1 2017
  • Atherosclerosis - Pipeline by MedImmune LLC, H1 2017
  • Atherosclerosis - Pipeline by Merck & Co Inc, H1 2017
  • Atherosclerosis - Pipeline by Omeros Corp, H1 2017
  • Atherosclerosis - Pipeline by Otsuka Holdings Co Ltd, H1 2017
  • Atherosclerosis - Pipeline by Resverlogix Corp, H1 2017
  • Atherosclerosis - Pipeline by Tolerys SA, H1 2017
  • Atherosclerosis - Pipeline by Unity Biotechnology Inc, H1 2017
  • Atherosclerosis - Pipeline by Vascular Biogenics Ltd, H1 2017
  • Atherosclerosis - Pipeline by Vericel Corp, H1 2017
  • Atherosclerosis - Pipeline by Vicore Pharma AB, H1 2017
  • Atherosclerosis - Pipeline by XBiotech Inc, H1 2017
  • Atherosclerosis - Dormant Projects, H1 2017
  • Atherosclerosis - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Atherosclerosis - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Atherosclerosis - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Atherosclerosis - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Atherosclerosis - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Atherosclerosis - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Atherosclerosis - Discontinued Products, H1 2017
  • Atherosclerosis - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Atherosclerosis, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top